Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AFT Pharmaceuticals Ltd. ( (AU:AFP) ) has shared an announcement.
AFT Pharmaceuticals announced at its Annual Shareholders’ Meeting that its research and development pipeline is targeting global markets worth over US$8 billion. The company is making significant progress with eight patented products and 24 off-patent injectables, along with advanced R&D programs entering commercialization in multiple international markets. AFT aims for a revenue goal of $300 million for FY27, supported by its robust product pipeline and geographic diversification, positioning it for sustained growth and long-term shareholder value creation.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a wide range of pharmaceutical products across various therapeutic categories. The company operates in major pharmaceutical distribution channels including over-the-counter, prescription, and hospital sectors. AFT’s product portfolio includes proprietary, in-licensed, patented, branded, and generic drugs. The company focuses on markets in Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, and the EU, while also out-licensing products to over 125 countries worldwide.
Average Trading Volume: 2,893
Technical Sentiment Signal: Hold
Current Market Cap: A$265M
For detailed information about AFP stock, go to TipRanks’ Stock Analysis page.